Cancer Screening

Our proprietary miRNA technology detects cancer at its earliest, most treatable stages. With minimally invasive test and accurate insights, our tests enable patients to act sooner.

A pioneering blood test for the early detection of gastric (stomach) cancer.

LUNGClear

A minimally invasive blood test designed to identify lung cancer at an early stage.

Cancer Treatment Selection

We leverage advanced Next-Generation Sequencing (NGS) technology to empower patients in personalised cancer treatment selection.

APEX Tissue

A Targeted 58-Gene Profiling Test

COMPASS Tissue

A Comprehensive 1021-Gene Profiling Test

Fortitude Kit 2.1

Multiplex Real-Time PCR Test Targeting ORF1ab for SARS-CoV-2

First

Second

Fortitude Kit 2.1

Mirxes Fortitude Kit 2.1 is a multiplex real-time PCR assay targeting the conserved regions ORF1ab region 1 (FAM) and ORF1ab region 2 (HEX) coupled with an internal spike-in plasmid control.

Limit of detection (LoD): 10 copies per reaction

No cross-reactivity with:

SARS-CoV-1 (SARS, identified in 2003)
Influenza A H1N1
Influenza A H3N2
Influenza B
MERS-CoV or EMC/2012 (MERS, identified in 2012)

More than 7 million Fortitude COVID-19 tests have been shipped to 13 hospitals and clinical labs in Singapore, and to more than 45 countries worldwide. Fortitude Kit 2.1 has received CE Mark and regulatory approval in Singapore, Philippines, Panama, Peru, Colombia, and Honduras.

Detects all variants of concern, including Delta and Omicron, as of 29 November 2021.

Ordering Information

Product	Pack Size	Contents	Catalogue No.
Fortitude Kit 2.1	200 reactions/kit	Primers-Probes Mix, Reverse Transcriptase, Universal Probes Reaction Mix, Positive Control, Negative Control	4480002 (IVD), 4480002R (RUO)

Note: The test is only provided for use by clinical laboratories.

Singapore (Global HQ)
Tel: +65 6816 2931
Email: sales@mirxes.com